Skip to main content

Severe Acute Malnutrition

3
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Dexa Medica
Dexa MedicaIndonesia - Tangerang
1 program
1
StriatinPhase 31 trial
Active Trials
NCT07089329Completed30Est. Apr 2026
Medica Corp
Medica CorpMA - Bedford
1 program
1
StriatinPhase 3
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Ready-to-use therapeutic food with heat stabilized rice branPhase 21 trial
Active Trials
NCT05319717Completed200Est. Aug 2023
Alliance Pharmaceuticals
3 programs
Improving the Outcomes of Community-based Management of Acute MalnutritionN/A1 trial
Nutritional Strategy - OptiMAN/A1 trial
The Responses to Illness Severity QuantificationN/A1 trial
Active Trials
NCT04582773Completed1,087Est. Oct 2020
NCT03751475Completed896Est. Jul 2020
NCT06123390Unknown20,000Est. Oct 2024
Innovation Pharmaceuticals
1 program
Severe Acute MalnutritionN/A1 trial
Active Trials
NCT03400930Completed473Est. Apr 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dexa MedicaStriatin
Colorado TherapeuticsReady-to-use therapeutic food with heat stabilized rice bran
Alliance PharmaceuticalsThe Responses to Illness Severity Quantification
Alliance PharmaceuticalsNutritional Strategy - OptiMA
Alliance PharmaceuticalsImproving the Outcomes of Community-based Management of Acute Malnutrition
Innovation PharmaceuticalsSevere Acute Malnutrition

Clinical Trials (6)

Total enrollment: 22,686 patients across 6 trials

NCT07089329Dexa MedicaStriatin

Efficacy of Striatin in Malnourished Children

Start: May 2025Est. completion: Apr 202630 patients
Phase 3Completed
NCT05319717Colorado TherapeuticsReady-to-use therapeutic food with heat stabilized rice bran

Rice Bran-based Supplemental Foods for the Treatment of Childhood Malnutrition

Start: Dec 2022Est. completion: Aug 2023200 patients
Phase 2Completed
NCT06123390Alliance PharmaceuticalsThe Responses to Illness Severity Quantification

Evaluating RISQ System Implementation in Acutely Malnourished Children in Chad (CRIMSON)

Start: Sep 2023Est. completion: Oct 202420,000 patients
N/AUnknown
NCT03751475Alliance PharmaceuticalsNutritional Strategy - OptiMA

Optimizing Acute Malnutrition Management in Children Aged 6 to 59 Months in Democratic Republic of Congo

Start: Jul 2019Est. completion: Jul 2020896 patients
N/ACompleted
NCT04582773Alliance PharmaceuticalsImproving the Outcomes of Community-based Management of Acute Malnutrition

Improving the Outcomes of Community-based Management of Acute Malnutrition

Start: Jul 2019Est. completion: Oct 20201,087 patients
N/ACompleted
NCT03400930Innovation PharmaceuticalsSevere Acute Malnutrition

Biomedical Investigations for Optimized Diagnosis and Monitoring of Severe Acute Malnutrition (SAM): Elucidating the Heterogeneous Diagnosis of SAM by Current Anthropometric Criteria and Moving Beyond

Start: Jan 2017Est. completion: Apr 2018473 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.